Mentolo Zeto

Mentolo Zeto may be available in the countries listed below.

Ingredient matches for Mentolo Zeto

Levomenthol

Levomenthol is reported as an ingredient of Mentolo Zeto in the following countries:

• Italy

International Drug Name Search

Profex

Profex may be available in the countries listed below.

Ingredient matches for Profex

Propafenone

Propafenone hydrochloride (a derivative of Propafenone) is reported as an ingredient of Profex in the following countries:

• Israel

International Drug Name Search

Sonke-Didanosine

Sonke-Didanosine may be available in the countries listed below.

Ingredient matches for Sonke-Didanosine

Didanosine

Didanosine is reported as an ingredient of Sonke-Didanosine in the following countries:

• South Africa

International Drug Name Search

Stopen

Stopen may be available in the countries listed below.

Ingredient matches for Stopen

Piroxicam

Piroxicam is reported as an ingredient of Stopen in the following countries:

• Colombia

International Drug Name Search

Prostica

Prostica may be available in the countries listed below.

Ingredient matches for Prostica

Flutamide

Flutamide is reported as an ingredient of Prostica in the following countries:

• Germany

International Drug Name Search

M-beta

M-beta may be available in the countries listed below.

Ingredient matches for M-beta

Morphine

Morphine sulphate pentahydrate (a derivative of Morphine) is reported as an ingredient of M-beta in the following countries:

• Germany

International Drug Name Search

Keftriaxone

Keftriaxone may be available in the countries listed below.

Ingredient matches for Keftriaxone

Ceftriaxone

Ceftriaxone disodium salt (a derivative of Ceftriaxone) is reported as an ingredient of Keftriaxone in the following countries:

• Georgia


• Israel

International Drug Name Search

Cefoxitina Normon

Cefoxitina Normon may be available in the countries listed below.

Ingredient matches for Cefoxitina Normon

Cefoxitin

Cefoxitin sodium salt (a derivative of Cefoxitin) is reported as an ingredient of Cefoxitina Normon in the following countries:

• Spain

International Drug Name Search

Apo-Propranolol

Apo-Propranolol may be available in the countries listed below.

Ingredient matches for Apo-Propranolol

Propranolol

Propranolol hydrochloride (a derivative of Propranolol) is reported as an ingredient of Apo-Propranolol in the following countries:

• Canada


• Vietnam

International Drug Name Search

Bromazépam EG

Bromazépam EG may be available in the countries listed below.

Ingredient matches for Bromazépam EG

Bromazepam

Bromazepam is reported as an ingredient of Bromazépam EG in the following countries:

• France

International Drug Name Search

Mebo

Mebo may be available in the countries listed below.

Ingredient matches for Mebo

Sitosterol, β-

Sitosterol, β- is reported as an ingredient of Mebo in the following countries:

• Ecuador


• Oman


• Tunisia

International Drug Name Search

Leucovorina Calcica

Leucovorina Calcica may be available in the countries listed below.

Ingredient matches for Leucovorina Calcica

Calcium Folinate

Calcium Folinate is reported as an ingredient of Leucovorina Calcica in the following countries:

• Argentina


• Ecuador


• Venezuela

International Drug Name Search

Adezio

Adezio may be available in the countries listed below.

Ingredient matches for Adezio

Cetirizine

Cetirizine dihydrochloride (a derivative of Cetirizine) is reported as an ingredient of Adezio in the following countries:

• Hong Kong


• Singapore


• Sri Lanka

International Drug Name Search

Ventolin Nebules

Ventolin Nebules may be available in the countries listed below.

Ingredient matches for Ventolin Nebules

Salbutamol

Salbutamol is reported as an ingredient of Ventolin Nebules in the following countries:

• Luxembourg

Salbutamol sulfate (a derivative of Salbutamol) is reported as an ingredient of Ventolin Nebules in the following countries:

• New Zealand


• Russian Federation

International Drug Name Search

Fosinopril Hydrochlorothiazide Mylan

Fosinopril Hydrochlorothiazide Mylan may be available in the countries listed below.

Ingredient matches for Fosinopril Hydrochlorothiazide Mylan

Fosinopril

Fosinopril sodium salt (a derivative of Fosinopril) is reported as an ingredient of Fosinopril Hydrochlorothiazide Mylan in the following countries:

• France

Hydrochlorothiazide

Hydrochlorothiazide is reported as an ingredient of Fosinopril Hydrochlorothiazide Mylan in the following countries:

• France

International Drug Name Search

Rogasti

Rogasti may be available in the countries listed below.

Ingredient matches for Rogasti

Famotidine

Famotidine is reported as an ingredient of Rogasti in the following countries:

• Israel

International Drug Name Search

Fosinoprilnatrium Actavis

Fosinoprilnatrium Actavis may be available in the countries listed below.

Ingredient matches for Fosinoprilnatrium Actavis

Fosinopril

Fosinopril sodium salt (a derivative of Fosinopril) is reported as an ingredient of Fosinoprilnatrium Actavis in the following countries:

• Netherlands

International Drug Name Search

Coatel

Coatel may be available in the countries listed below.

Ingredient matches for Coatel

Hypromellose

Hypromellose is reported as an ingredient of Coatel in the following countries:

• Turkey

International Drug Name Search

Propylthiouracile

Propylthiouracile may be available in the countries listed below.

Ingredient matches for Propylthiouracile

Propylthiouracil

Propylthiouracile (DCF) is known as Propylthiouracil in the US.

International Drug Name Search

Glossary

DCF	Dénomination Commune Française

Click for further information on drug naming conventions and International Nonproprietary Names.

Genticol

Genticol may be available in the countries listed below.

Ingredient matches for Genticol

Gentamicin

Gentamicin sulfate (a derivative of Gentamicin) is reported as an ingredient of Genticol in the following countries:

• Italy


• Romania

International Drug Name Search

Polyspectran Salbe

Polyspectran Salbe may be available in the countries listed below.

Ingredient matches for Polyspectran Salbe

Bacitracin

Bacitracin is reported as an ingredient of Polyspectran Salbe in the following countries:

• Germany

Neomycin

Neomycin sulfate (a derivative of Neomycin) is reported as an ingredient of Polyspectran Salbe in the following countries:

• Germany

Polymyxin B

Polymyxin B sulfate (a derivative of Polymyxin B) is reported as an ingredient of Polyspectran Salbe in the following countries:

• Germany

International Drug Name Search

Glotamuc

Glotamuc may be available in the countries listed below.

Ingredient matches for Glotamuc

Acetylcysteine

Acetylcysteine is reported as an ingredient of Glotamuc in the following countries:

• Vietnam

International Drug Name Search

Daunorubicin Pfizer

Daunorubicin Pfizer may be available in the countries listed below.

Ingredient matches for Daunorubicin Pfizer

Daunorubicin

Daunorubicin hydrochloride (a derivative of Daunorubicin) is reported as an ingredient of Daunorubicin Pfizer in the following countries:

• Singapore

International Drug Name Search

Mucolase

Mucolase may be available in the countries listed below.

Ingredient matches for Mucolase

Carbocisteine

Carbocisteine is reported as an ingredient of Mucolase in the following countries:

• Italy

International Drug Name Search

Mucinex

In the US, Mucinex (guaifenesin systemic) is a member of the drug class expectorants and is used to treat Bronchitis, Cough and Fibromyalgia.

US matches:

• Mucinex


• Mucinex D


• Mucinex Children's Granules


• Mucinex Cough Mini-Melts Granule Packets


• Mucinex Junior Strength Granules


• Mucinex Sustained-Release Tablets


• Mucinex Children's Cold


• Mucinex Children's Cough


• Mucinex DM


• Mucinex Full Force


• Mucinex Moisture Smart


• Mucinex D Maximum Strength


• Mucinex DM Maximum Strength


• Mucinex Maximum Strength


• Mucinex Nasal Spray


• Mucinex for Kids

Ingredient matches for Mucinex

Guaifenesin

Guaifenesin is reported as an ingredient of Mucinex in the following countries:

• United States

International Drug Name Search

Estima

Estima may be available in the countries listed below.

Ingredient matches for Estima

Progesterone

Progesterone is reported as an ingredient of Estima in the following countries:

• France

International Drug Name Search

Magnabiotic

Magnabiotic may be available in the countries listed below.

Ingredient matches for Magnabiotic

Azithromycin

Azithromycin is reported as an ingredient of Magnabiotic in the following countries:

• Dominican Republic

International Drug Name Search

Eromycin

Eromycin may be available in the countries listed below.

Ingredient matches for Eromycin

Erythromycin

Erythromycin is reported as an ingredient of Eromycin in the following countries:

• Bahrain

Erythromycin stearate (a derivative of Erythromycin) is reported as an ingredient of Eromycin in the following countries:

• Bangladesh


• Oman

International Drug Name Search

Kuppam

Kuppam may be available in the countries listed below.

Ingredient matches for Kuppam

Pantoprazole

Pantoprazole sodium (a derivative of Pantoprazole) is reported as an ingredient of Kuppam in the following countries:

• Mexico

International Drug Name Search

Aqueous Charcodote

Aqueous Charcodote may be available in the countries listed below.

Ingredient matches for Aqueous Charcodote

Charcoal

Charcoal, Activated is reported as an ingredient of Aqueous Charcodote in the following countries:

• Singapore

International Drug Name Search

Melengestrol Acetate

Melengestrol Acetate may be available in the countries listed below.

Ingredient matches for Melengestrol Acetate

Melengestrol

Melengestrol Acetate (USAN) is also known as Melengestrol (Rec.INN)

International Drug Name Search

Glossary

Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Mytoplastine

Mytoplastine may be available in the countries listed below.

Ingredient matches for Mytoplastine

Zinc Oxide

Zinc Oxide is reported as an ingredient of Mytoplastine in the following countries:

• Tunisia

International Drug Name Search

Striadyne

Striadyne may be available in the countries listed below.

Ingredient matches for Striadyne

Adenosine Triphosphate

Adenosine Triphosphate disodium salt (a derivative of Adenosine Triphosphate) is reported as an ingredient of Striadyne in the following countries:

• France

International Drug Name Search

Firazyr

Firazyr may be available in the countries listed below.

UK matches:

• Firazyr 30 mg solution for injection in pre-filled syringe (SPC)

Ingredient matches for Firazyr

Icatibant

Icatibant is reported as an ingredient of Firazyr in the following countries:

• Greece


• Luxembourg

Icatibant acetate (a derivative of Icatibant) is reported as an ingredient of Firazyr in the following countries:

• Austria


• Finland


• France


• Germany


• Spain


• Sweden


• Switzerland


• United Kingdom

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.

Glycafor

Glycafor may be available in the countries listed below.

Ingredient matches for Glycafor

Gliclazide

Gliclazide is reported as an ingredient of Glycafor in the following countries:

• Indonesia

International Drug Name Search

Celbarin

Celbarin may be available in the countries listed below.

Ingredient matches for Celbarin

Ribavirin

Ribavirin is reported as an ingredient of Celbarin in the following countries:

• Bangladesh

International Drug Name Search

Feedmix Trim / Sul

Feedmix Trim/Sul may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Feedmix Trim/Sul

Sulfadiazine

Sulfadiazine sodium (a derivative of Sulfadiazine) is reported as an ingredient of Feedmix Trim/Sul in the following countries:

• Netherlands

Trimethoprim

Trimethoprim is reported as an ingredient of Feedmix Trim/Sul in the following countries:

• Netherlands

International Drug Name Search

Pedipur

Pedipur may be available in the countries listed below.

Ingredient matches for Pedipur

Methenamine

Methenamine is reported as an ingredient of Pedipur in the following countries:

• Poland

International Drug Name Search

Fluoxetin-RPh

Fluoxetin-RPh may be available in the countries listed below.

Ingredient matches for Fluoxetin-RPh

Fluoxetine

Fluoxetine hydrochloride (a derivative of Fluoxetine) is reported as an ingredient of Fluoxetin-RPh in the following countries:

• Germany

International Drug Name Search

Nifédipine EG

Nifédipine EG may be available in the countries listed below.

Ingredient matches for Nifédipine EG

Nifedipine

Nifedipine is reported as an ingredient of Nifédipine EG in the following countries:

• France

International Drug Name Search

Ketok

Ketok may be available in the countries listed below.

Ingredient matches for Ketok

Ketoprofen

Ketoprofen is reported as an ingredient of Ketok in the following countries:

• Japan

International Drug Name Search

Unikpef

Unikpef may be available in the countries listed below.

Ingredient matches for Unikpef

Pefloxacin

Pefloxacin is reported as an ingredient of Unikpef in the following countries:

• Russian Federation

International Drug Name Search

Pergotime

Pergotime may be available in the countries listed below.

Ingredient matches for Pergotime

Clomifene

Clomifene citrate (a derivative of Clomifene) is reported as an ingredient of Pergotime in the following countries:

• Belgium


• Denmark


• France


• Iceland


• Luxembourg


• Norway


• Sweden

International Drug Name Search

Zoter

Zoter may be available in the countries listed below.

Ingredient matches for Zoter

Acyclovir

Aciclovir is reported as an ingredient of Zoter in the following countries:

• Indonesia

International Drug Name Search

Cibadrex

Cibadrex may be available in the countries listed below.

Ingredient matches for Cibadrex

Benazepril

Benazepril hydrochloride (a derivative of Benazepril) is reported as an ingredient of Cibadrex in the following countries:

• Bahrain


• Bulgaria


• France


• Germany


• Ghana


• Greece


• Kenya


• Luxembourg


• Nigeria


• South Africa


• Spain


• Sudan


• Switzerland


• Tanzania


• Zimbabwe

Hydrochlorothiazide

Hydrochlorothiazide is reported as an ingredient of Cibadrex in the following countries:

• Bahrain


• Bulgaria


• France


• Germany


• Greece


• Luxembourg


• South Africa


• Spain


• Switzerland

International Drug Name Search

Salden

Salden may be available in the countries listed below.

Ingredient matches for Salden

Salbutamol

Salbutamol sulfate (a derivative of Salbutamol) is reported as an ingredient of Salden in the following countries:

• Costa Rica


• Ecuador


• El Salvador


• Guatemala


• Honduras


• Nicaragua


• Panama

International Drug Name Search

Albalon

In the US, Albalon (naphazoline ophthalmic) is a member of the drug class ophthalmic antihistamines and decongestants and is used to treat Eye Dryness/Redness and Eye Redness/Itching.

US matches:

• Albalon

Ingredient matches for Albalon

Naphazoline

Naphazoline hydrochloride (a derivative of Naphazoline) is reported as an ingredient of Albalon in the following countries:

• Australia


• Bahrain


• Hong Kong


• Luxembourg


• Netherlands


• New Zealand


• Oman


• Thailand


• United States

International Drug Name Search

Fungafite

Fungafite may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Fungafite

Miconazole

Miconazole nitrate (a derivative of Miconazole) is reported as an ingredient of Fungafite in the following countries:

• Australia

International Drug Name Search

Ciprofibrate

UK matches:

• Ciprofibrate 100mg Tablets

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

C10AB08

CAS registry number (Chemical Abstracts Service)

0052214-84-3

Chemical Formula

C13-H14-Cl2-O3

Molecular Weight

289

Therapeutic Category

Antilipemic agent, fibrate

Chemical Name

Propanoic acid, 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methyl-

Foreign Names

• Ciprofibratum (Latin)
• Ciprofibrat (German)
• Ciprofibrate (French)
• Ciprofibrato (Spanish)

Generic Names

• Ciprofibrate (OS: USAN, DCF, BAN)
• Win 35833 (IS: Winthrop)
• Ciprofibrate (PH: BP 2010, Ph. Eur. 6)
• Ciprofibratum (PH: Ph. Eur. 6)

Brand Names

• Cetaxin
  AC Farma, Peru



• Ciprofibrate Almus
  Almus, France



• Ciprofibrate Arrow
  Arrow, France



• Ciprofibrate Biogaran
  Biogaran, France



• Ciprofibrate Mylan
  Mylan, Belgium; Mylan, France



• Ciprofibrate Qualimed
  Qualimed, France



• Ciprofibrate Ratiopharm
  Ratiopharm, France



• Ciprofibrate RPG
  RPG, France



• Ciprofibrate Sandoz
  Sandoz, France



• Ciprofibrate Teva
  Teva Santé, France



• Ciprofibrate Winthrop
  Sanofi-Aventis, France



• Ciprofibrato
  Caferma, Peru



• Estabinol
  Panalab, Peru



• Estaprol
  Sanofi-Aventis, Argentina; Sanofi-Aventis, Chile



• Hiperlipen
  Sanofi-Aventis, Colombia; Sanofi-Aventis, Costa Rica; Sanofi-Aventis, Dominican Republic; Sanofi-Aventis, Ecuador; Sanofi-Aventis, Guatemala; Sanofi-Aventis, Honduras; Sanofi-Aventis, Nicaragua; Sanofi-Aventis, Panama; Sanofi-Aventis, Peru; Sanofi-Aventis, El Salvador; Sanofi-Aventis, Venezuela



• Hyperlipen
  Sanofi-Aventis, Belgium; Sanofi-Aventis, Switzerland; Sanofi-Synthelabo, Luxembourg



• Lipanor
  Sanofi Aventis, Tunisia; Sanofi-Aventis, Bulgaria; Sanofi-Aventis, Czech Republic; Sanofi-Aventis, Estonia; Sanofi-Aventis, France; Sanofi-Aventis, Hungary; Sanofi-Aventis, Israel; Sanofi-Aventis, Lithuania; Sanofi-Aventis, Latvia; Sanofi-Aventis, Poland; Sanofi-Aventis, Romania; Sanofi-Aventis, Serbia; Sanofi-Aventis, Slovakia; Sanofi-Aventis - Produtos farmacêuticos, S.A., Portugal



• Modalim
  Sanofi-Aventis, Indonesia; Sanofi-Aventis, Malaysia; Sanofi-Aventis, Netherlands; Sanofi-Aventis, Singapore; Sanofi-Aventis, Vietnam; Winthrop Pharmaceuticals, United Kingdom



• Oroxadin
  Sanofi-Aventis, Brazil; Sanofi-Aventis, Mexico



• Savilen
  Sanofi-Synthelabo, Greece

International Drug Name Search

Glossary

BAN	British Approved Name
DCF	Dénomination Commune Française
IS	Inofficial Synonym
OS	Official Synonym
PH	Pharmacopoeia Name
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Ofirmev Injection

Pronunciation: a-SEET-a-MIN-oh-fen
Generic Name: Acetaminophen
Brand Name: Ofirmev

Ofirmev Injection is used for:

Managing mild to moderate pain and for reducing fever. It is also used to manage moderate to severe pain when used along with opioid pain medicines (eg, oxycodone).

Ofirmev Injection is an analgesic and antipyretic (lowers fever). Exactly how it works is not known but it is thought to work by lowering a chemical in the brain that stimulates pain nerves and the heat-regulating center in the brain.

Do NOT use Ofirmev Injection if:

• you are allergic to any ingredient in Ofirmev Injection


• you have severe liver problems

Contact your doctor or health care provider right away if any of these apply to you.

Before using Ofirmev Injection:

Some medical conditions may interact with Ofirmev Injection. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have a history of alcohol abuse or you drink more than 3 alcohol-containing drinks every day


• if you have liver problems (eg, hepatitis), poor nutrition, low blood volume (eg, caused by dehydration or blood loss), or kidney problems

Some MEDICINES MAY INTERACT with Ofirmev Injection. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Anticoagulants (eg, warfarin) because the risk of their side effects, including bleeding, may be increased by Ofirmev Injection


• Isoniazid or other medicines that may harm the liver (eg, methotrexate, ketoconazole, certain medicines for HIV infection) because the risk of liver problems may be increased. Ask your doctor if you are unsure if any of your medicines might harm the liver

This may not be a complete list of all interactions that may occur. Ask your health care provider if Ofirmev Injection may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Ofirmev Injection:

Use Ofirmev Injection as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Ofirmev Injection is usually given as an injection at your doctor's office, hospital, or clinic. If you will be using Ofirmev Injection at home, a health care provider will teach you how to use it. Be sure you understand how to use Ofirmev Injection. Follow the procedures you are taught when you use a dose. Contact your health care provider if you have any questions.


• Do not mix other medicines (especially chlorpromazine or diazepam) in the same container or IV line as Ofirmev Injection. Contact your health care provider if you have any questions about how to give Ofirmev Injection with other medicines.


• Do not use Ofirmev Injection if it contains particles, is cloudy or discolored, or if the vial is cracked or damaged.


• Use Ofirmev Injection within 6 hours after opening.


• If you miss a dose of Ofirmev Injection and you are using it regularly, use it as soon as possible. If several hours have passed or if it is nearing time for the next dose, do not double the dose to catch up, unless advised by your health care provider. Do not use 2 doses at once.

Ask your health care provider any questions you may have about how to use Ofirmev Injection.

Important safety information:

• Ofirmev Injection has acetaminophen in it. Before you start any new medicine, check the label to see if it has acetaminophen in it too. If it does or if you are not sure, check with your doctor or pharmacist.


• Ofirmev Injection may harm your liver. Your risk may be greater if you drink alcohol while you are using Ofirmev Injection or if you use Ofirmev Injection in high doses. Talk to your doctor before you use Ofirmev Injection or other fever reducers if you drink more than 3 drinks with alcohol per day. Do NOT use more than the recommended dose without checking with your doctor.


• Ofirmev Injection should be used with extreme caution in CHILDREN younger than 2 years old; safety and effectiveness in these children have not been confirmed.


• PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Ofirmev Injection while you are pregnant. Ofirmev Injection is found in breast milk. If you are or will be breast-feeding while you use Ofirmev Injection, check with your doctor. Discuss any possible risks to your baby.

Possible side effects of Ofirmev Injection:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Constipation, headache, mild nausea or vomiting, or trouble sleeping.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, throat, or tongue); agitation or anxiety; dark urine or pale stools; fainting; fast heartbeat; muscle pain, spasms, weakness, or cramping; pain, redness, or swelling at the injection site; persistent spasm of the jaw muscles; severe or persistent headache or dizziness; shortness of breath; stomach pain; swelling of the hands, ankles, or feet; unusual tiredness or weakness; wheezing; yellowing of the skin or eyes.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Ofirmev side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include coma; dark urine; decreased urination; excessive sweating; extreme fatigue; nausea and vomiting; pale stools; stomach pain; unusual bruising or bleeding; yellowing of the skin or eyes.

Proper storage of Ofirmev Injection:

Ofirmev Injection is usually handled and stored by a health care provider. If you are using Ofirmev Injection at home, store Ofirmev Injection as directed by your pharmacist or health care provider. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Ofirmev Injection out of the reach of children and away from pets.

General information:

• If you have any questions about Ofirmev Injection, please talk with your doctor, pharmacist, or other health care provider.


• Ofirmev Injection is to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Ofirmev Injection. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Ofirmev resources

• Ofirmev Side Effects (in more detail)
• Ofirmev Use in Pregnancy & Breastfeeding
• Ofirmev Drug Interactions
• Ofirmev Support Group
• 0 Reviews for Ofirmev - Add your own review/rating

Compare Ofirmev with other medications

• Fever
• Pain

Risperidona Sandoz

Risperidona Sandoz may be available in the countries listed below.

Ingredient matches for Risperidona Sandoz

Risperidone

Risperidone is reported as an ingredient of Risperidona Sandoz in the following countries:

• Portugal


• Spain

International Drug Name Search

Méphénésine

Méphénésine may be available in the countries listed below.

Ingredient matches for Méphénésine

Mephenesin

Méphénésine (DCF) is also known as Mephenesin (Rec.INN)

International Drug Name Search

Glossary

DCF	Dénomination Commune Française
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.

Ciprofloxacino Vir

Ciprofloxacino Vir may be available in the countries listed below.

Ingredient matches for Ciprofloxacino Vir

Ciprofloxacin

Ciprofloxacin hydrochloride (a derivative of Ciprofloxacin) is reported as an ingredient of Ciprofloxacino Vir in the following countries:

• Spain

International Drug Name Search

Zestril

Zestril is a brand name of lisinopril, approved by the FDA in the following formulation(s):

ZESTRIL (lisinopril - tablet; oral)

• 
  Manufacturer: ASTRAZENECA
  
  Approval date: May 19, 1988
  
  Strength(s): 10MG ^[AB], 20MG ^[AB], 40MG ^[RLD][AB], 5MG ^[AB]


• 
  Manufacturer: ASTRAZENECA
  
  Approval date: April 29, 1993
  
  Strength(s): 2.5MG ^[AB]


• 
  Manufacturer: ASTRAZENECA
  
  Approval date: January 20, 1999
  
  Strength(s): 30MG ^[AB]

Has a generic version of Zestril been approved?

Yes. The following products are equivalent to Zestril:

lisinopril tablet; oral

• 
  Manufacturer: APOTEX INC
  
  Approval date: September 30, 2002
  
  Strength(s): 10MG ^[AB], 2.5MG ^[AB], 20MG ^[AB], 30MG ^[AB], 40MG ^[AB], 5MG ^[AB]


• 
  Manufacturer: AUROBINDO
  
  Approval date: February 22, 2006
  
  Strength(s): 10MG ^[AB], 2.5MG ^[AB], 20MG ^[AB], 30MG ^[AB], 40MG ^[AB], 5MG ^[AB]


• 
  Manufacturer: IVAX SUB TEVA PHARMS
  
  Approval date: July 1, 2002
  
  Strength(s): 10MG ^[AB], 2.5MG ^[AB], 20MG ^[AB], 30MG ^[AB], 40MG ^[AB], 5MG ^[AB]


• 
  Manufacturer: LEK PHARMS
  
  Approval date: July 1, 2002
  
  Strength(s): 10MG ^[AB], 2.5MG ^[AB], 20MG ^[AB], 30MG ^[AB], 40MG ^[AB], 5MG ^[AB]


• 
  Manufacturer: LUPIN
  
  Approval date: September 9, 2005
  
  Strength(s): 10MG ^[AB], 2.5MG ^[AB], 20MG ^[AB], 30MG ^[AB], 40MG ^[AB], 5MG ^[AB]


• 
  Manufacturer: MYLAN
  
  Approval date: July 1, 2002
  
  Strength(s): 10MG ^[AB], 2.5MG ^[AB], 20MG ^[AB], 30MG ^[AB], 40MG ^[AB], 5MG ^[AB]


• 
  Manufacturer: PRINSTON INC
  
  Approval date: July 1, 2002
  
  Strength(s): 10MG ^[AB], 2.5MG ^[AB], 20MG ^[AB], 30MG ^[AB], 40MG ^[AB], 5MG ^[AB]


• 
  Manufacturer: RANBAXY
  
  Approval date: July 1, 2002
  
  Strength(s): 10MG ^[AB], 2.5MG ^[AB], 20MG ^[AB], 40MG ^[AB], 5MG ^[AB]


• 
  Manufacturer: RANBAXY
  
  Approval date: February 11, 2003
  
  Strength(s): 30MG ^[AB]


• 
  Manufacturer: SANDOZ
  
  Approval date: July 1, 2002
  
  Strength(s): 10MG ^[AB], 10MG ^[AB], 2.5MG ^[AB], 2.5MG ^[AB], 20MG ^[AB], 20MG ^[AB], 30MG ^[AB], 30MG ^[AB], 40MG ^[AB], 40MG ^[AB], 5MG ^[AB], 5MG ^[AB]


• 
  Manufacturer: VINTAGE
  
  Approval date: July 1, 2002
  
  Strength(s): 10MG ^[AB], 2.5MG ^[AB], 20MG ^[AB], 30MG ^[AB], 40MG ^[AB], 5MG ^[AB]


• 
  Manufacturer: WATSON LABS
  
  Approval date: July 1, 2002
  
  Strength(s): 10MG ^[AB], 2.5MG ^[AB], 20MG ^[AB], 30MG ^[AB], 40MG ^[AB], 5MG ^[AB]


• 
  Manufacturer: WEST WARD
  
  Approval date: July 1, 2002
  
  Strength(s): 10MG ^[AB], 2.5MG ^[AB], 20MG ^[AB], 40MG ^[AB], 5MG ^[AB]


• 
  Manufacturer: WEST WARD
  
  Approval date: June 27, 2003
  
  Strength(s): 30MG ^[AB]


• 
  Manufacturer: WOCKHARDT
  
  Approval date: April 19, 2007
  
  Strength(s): 10MG ^[AB], 2.5MG ^[AB], 20MG ^[AB], 30MG ^[AB], 40MG ^[AB], 5MG ^[AB]

PRINIVIL (lisinopril tablet; oral)

• 
  Manufacturer: MERCK
  
  Approval date: December 29, 1987
  
  Strength(s): 10MG ^[AB], 20MG ^[AB], 5MG ^[AB]


• 
  Manufacturer: MERCK
  
  Approval date: October 25, 1988
  
  Strength(s): 40MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zestril. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Zestril.

See also...

• Zestril Consumer Information (Drugs.com)
• Zestril Consumer Information (Wolters Kluwer)
• Zestril Consumer Information (Cerner Multum)
• Zestril Advanced Consumer Information (Micromedex)
• Lisinopril Consumer Information (Drugs.com)
• Lisinopril Consumer Information (Wolters Kluwer)
• Lisinopril Consumer Information (Cerner Multum)
• Lisinopril Advanced Consumer Information (Micromedex)
• Lisinopril AHFS DI Monographs (ASHP)

Gemfi-1A Pharma

Gemfi-1A Pharma may be available in the countries listed below.

Ingredient matches for Gemfi-1A Pharma

Gemfibrozil

Gemfibrozil is reported as an ingredient of Gemfi-1A Pharma in the following countries:

• Germany

International Drug Name Search

Ponstel

In the US, Ponstel (mefenamic acid systemic) is a member of the drug class nonsteroidal anti-inflammatory agents and is used to treat Pain and Period Pain.

US matches:

• Ponstel

Ingredient matches for Ponstel

Mefenamic Acid

Mefenamic Acid is reported as an ingredient of Ponstel in the following countries:

• South Africa


• United States

International Drug Name Search

Panokase

In the US, Panokase (pancrelipase systemic) is a member of the drug class digestive enzymes and is used to treat Chronic Pancreatitis, Cystic Fibrosis and Pancreatic Exocrine Dysfunction.

US matches:

• Panokase

Ingredient matches for Panokase

Pancrelipase

Pancrelipase is reported as an ingredient of Panokase in the following countries:

• United States

International Drug Name Search

Lidocain-Epinephrin Streuli

Lidocain-Epinephrin Streuli may be available in the countries listed below.

Ingredient matches for Lidocain-Epinephrin Streuli

Epinephrine

Epinephrine is reported as an ingredient of Lidocain-Epinephrin Streuli in the following countries:

• Switzerland

Lidocaine

Lidocaine hydrochloride (a derivative of Lidocaine) is reported as an ingredient of Lidocain-Epinephrin Streuli in the following countries:

• Switzerland

International Drug Name Search

Lévanol

Lévanol may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Lévanol

Levamisole

Levamisole hydrochloride (a derivative of Levamisole) is reported as an ingredient of Lévanol in the following countries:

• France

International Drug Name Search

Cetirizina Pensa

Cetirizina Pensa may be available in the countries listed below.

Ingredient matches for Cetirizina Pensa

Cetirizine

Cetirizine dihydrochloride (a derivative of Cetirizine) is reported as an ingredient of Cetirizina Pensa in the following countries:

• Italy

International Drug Name Search

Ventolin Diskus

Ventolin Diskus may be available in the countries listed below.

Ingredient matches for Ventolin Diskus

Salbutamol

Salbutamol is reported as an ingredient of Ventolin Diskus in the following countries:

• Ireland

Salbutamol sulfate (a derivative of Salbutamol) is reported as an ingredient of Ventolin Diskus in the following countries:

• Czech Republic


• Iceland


• Israel


• Luxembourg


• Romania

International Drug Name Search

Helminex

Helminex may be available in the countries listed below.

Ingredient matches for Helminex

Flubendazole

Flubendazole is reported as an ingredient of Helminex in the following countries:

• Peru

International Drug Name Search

Veratide

Veratide may be available in the countries listed below.

Ingredient matches for Veratide

Hydrochlorothiazide

Hydrochlorothiazide is reported as an ingredient of Veratide in the following countries:

• Germany

Triamterene

Triamterene is reported as an ingredient of Veratide in the following countries:

• Germany

Verapamil

Verapamil hydrochloride (a derivative of Verapamil) is reported as an ingredient of Veratide in the following countries:

• Germany

International Drug Name Search

Tetrex

Tetrex may be available in the countries listed below.

Ingredient matches for Tetrex

Tetracycline

Tetracycline hydrochloride (a derivative of Tetracycline) is reported as an ingredient of Tetrex in the following countries:

• Brazil


• Ethiopia


• Mexico

International Drug Name Search

Blokyleate

Blokyleate may be available in the countries listed below.

Ingredient matches for Blokyleate

Carteolol

Carteolol hydrochloride (a derivative of Carteolol) is reported as an ingredient of Blokyleate in the following countries:

• Japan

International Drug Name Search

Kalium Chloratum Leciva

Kalium Chloratum Leciva may be available in the countries listed below.

Ingredient matches for Kalium Chloratum Leciva

Potassium Chloride

Potassium Chloride is reported as an ingredient of Kalium Chloratum Leciva in the following countries:

• Czech Republic


• Slovakia

International Drug Name Search

Rasburicase

Class: Enzymes
ATC Class: V03AF07
VA Class: GA500
Chemical Name: urate (Aspergillus flavus clone 9C/9A reduced) oxidase
Molecular Formula: C₁₅₂₃H₂₃₈₃N₄₁₇O₄₆₂S₇ (monomer)
CAS Number: 134774-45-1
Brands: Elitek

• Anaphylaxis


• 
  

  Risk of severe hypersensitivity reactions (e.g., anaphylaxis).^a (See Hypersensitivity Reactions under Cautions.)

  
  


• 
  

  Immediately and permanently discontinue if clinical evidence of hypersensitivity reaction develops.^a

  
  

• Hemolysis


• 
  

  Risk of severe hemolysis in patients with a glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.^a (See Hemolysis under Cautions.)

  
  


• 
  

  Immediately and permanently discontinue if hemolysis develops.^a

  
  


• 
  

  Screen patients at higher risk (e.g., patients of African or Mediterranean ancestry) prior to starting therapy.^a

  
  

• Methemoglobinemia


• 
  

  Methemoglobinemia reported; immediately and permanently discontinue if methemoglobinemia develops.^a (See Methemoglobinemia under Cautions.)

  
  

• Interference with Uric Acid Measurements


• 
  

  Enzymatic degradation of uric acid occurs within blood samples left at room temperature, resulting in spuriously low uric acid levels.^a

  
  


• 
  

  Collect blood in prechilled tubes containing heparin anticoagulant and immediately immerse and maintain in an ice-water bath; assay plasma samples within 4 hours of collection.^a (See Specific Drugs and Laboratory Tests under Interactions.)

  
  

Introduction

Biosynthethic (recombinant DNA origin) form of urate oxidase prepared from a genetically modified strain of Saccharomyces cerevisiae.^{1 4 5 6}

Uses for Rasburicase

Chemotherapy-induced Hyperuricemia

Initial management of plasma uric acid concentrations in pediatric patients with leukemia, lymphoma, or solid tumors who are receiving chemotherapy expected to result in tumor lysis and subsequent elevation of plasma uric acid concentrations.^{1 2 3 4 5 6}

Rasburicase Dosage and Administration

General

• 
  

  Initiate chemotherapy 4–24 hours after administering first dose of rasburicase.¹

  
  


• 
  

  Administer concomitantly with IV hydration according to standard medical practice for management of plasma uric acid in patients at risk for tumor lysis syndrome.¹

  
  

Administration

IV Administration

Administer by IV infusion.¹

Do not administer as a rapid IV injection (e.g., IV push or bolus).¹

Do not use filters during administration.¹

Infuse through a different line than that used for other concomitant drugs; if not possible, flush the line with at least 15 mL of 0.9% sodium chloride injection prior to and after infusion of rasburicase solutions.¹

Reconstitution

Reconstitute prior to administration.¹

Determine number of vials needed to achieve the proper dosage based on the patient’s weight and the dose per kg.¹

Reconstitute vial containing 1.5 mg of rasburicase lyophilized powder with 1 mL of provided diluent (sterile water for injection and poloxamer 188) to provide a solution containing 1.5 mg of rasburicase per mL.¹

Mix by swirling very gently.¹ Do not shake or form a vortex.¹

Must be diluted further before IV administration.^a

Dilution

Use strict aseptic technique since drug product contains no preservatives.¹

Withdraw appropriate dose from reconstituted vials and add to the appropriate volume of 0.9% sodium chloride injection to achieve a final volume of 50 mL.¹

Rate of Administration

Administer diluted solution by IV infusion over 30 minutes.¹

Dosage

Pediatric Patients

Chemotherapy-induced Hyperuricemia

IV

Infants and children 1 month to 17 years of age: 0.15 or 0.2 mg/kg once daily for 5 days.¹

Safety and efficacy established only for a single course of treatment.¹ (See Sensitivity Reactions under Cautions.)

Prescribing Limits

Pediatric Patients

Chemotherapy-induced Hyperuricemia

IV

Infants and children 1 month to 17 years of age: Safety and efficacy of twice daily dosing, dosing for >5 days, or administration of >1 course of therapy not established.¹

Special Populations

No special populations dosing recommendations at this time.¹

Cautions for Rasburicase

Contraindications

• 
  

  G-6-PD deficiency.¹ (See Hemolysis under Cautions.)

  
  


• 
  

  Known hemolytic reactions to rasburicase or any ingredient in the formulation.¹ (See Hemolysis under Cautions.)

  
  


• 
  

  Known methemoglobinemia reactions to rasburicase or any ingredient in the formulation.¹ (See Methemoglobinemia under Cautions.)

  
  


• 
  

  Known hypersensitivity to rasburicase or any ingredient in the formulation.¹

  
  

Warnings/Precautions

Warnings

Hemolysis

Potential for severe (e.g., grade 3 or 4) hemolytic reactions associated with G-6-PD deficiency; reported within 2–4 days of initiation of therapy.¹

Immediately and permanently discontinue the drug if evidence of hemolysis appears; initiate appropriate patient monitoring and supportive measures (e.g., transfusion support).¹

Contraindicated in patients with G-6-PD deficiency because hydrogen peroxide is a major product of the conversion of uric acid to allantoin.¹

Prior to initiating therapy, screen patients at increased risk of G-6-PD deficiency (e.g., patients of African or Mediterranean descent).¹

Methemoglobinemia

Risk of methemoglobinemia, resulting in serious hypoxemia requiring medical intervention.¹

Immediately and permanently discontinue if methemoglobinemia develops and implement supportive measures (e.g., transfusion support, methylene blue administration).¹

Unknown whether a deficiency of cytochrome b₅ reductase (methemoglobin reductase) or of other antioxidant enzymes increases risk for methemoglobinemia or hemolytic anemia.¹

Sensitivity Reactions

Hypersensitivity Reactions

Risk of severe hypersensitivity reactions (e.g., anaphylaxis); may occur any time during treatment, even during the first dose.¹

If a serious hypersensitivity reaction occurs(e.g., bronchospasm, chest pain and tightness, dyspnea, hypoxia, hypotension, shock, and/or urticaria), immediately and permanently discontinue drug and initiate appropriate therapy.¹

Safety in patients with atopic allergy or asthma is unknown.^{2 3 6}

General Precautions

Hydration

Maintain adequate hydration according to standard medical practice for the management of plasma uric acid in patients at risk for tumor lysis syndrome.¹ Alkalinization of the urine is not needed.^{6 9}

Immunogenicity

Antibodies to rasburicase may develop; may be associated with inhibition of rasburicase activity.¹

Specific Populations

Pregnancy

Category C.¹

Lactation

Not known whether rasburicase is distributed into milk; discontinue nursing or the drug.¹

Pediatric Use

Safety and efficacy not established in infants <1 month of age.^a

Geriatric Use

Insufficient experience in those ≥65 years of age to determine whether they respond differently than pediatric patients.^a

Adult Use

Insufficient experience in adults to determine whether they respond differently than pediatric patients.^a

Common Adverse Effects

Vomiting, fever, nausea, headache, abdominal pain, constipation, diarrhea, mucositis, rash.¹

Interactions for Rasburicase

Does not substantially induce or inhibit CYP isoenzymes including 1A, 2A, 2B, 2C, 2E, or 3A in vivo; clinically relevant pharmacokinetic interactions unlikely.¹

Specific Drugs and Laboratory Tests

Drug or Test	Interaction	Comments
Allopurinol	Pharmacokinetic interactions unlikely1
Antineoplastic agents (cyclophosphamide, cytarabine, daunorubicin, etoposide, mercaptopurine, methotrexate, thioguanine, vincristine)	Pharmacokinetic interactions unlikely1
Methylprednisolone	Pharmacokinetic interactions unlikely1
Test for uric acid	Interference with uric acid measurements due to enzymatic degradation of uric acid in blood/plasma/serum samples left at room temperature, resulting in spuriously low uric acid concentrations1	Collect blood samples in prechilled test tubes containing heparin and immediately immerse in an ice water bath1 Analyze uric acid concentrations in plasma; prepare plasma samples from whole blood by centrifugation in a precooled centrifuge (4°C) and assay within 4 hours of sample collection1

Rasburicase Pharmacokinetics

Pharmacokinetics evaluated in pediatric patients; insufficient data available to evaluate pharmacokinetics in adults.¹

Absorption

Onset

Age-adjusted target plasma uric acid concentrations (i.e., ≤6.5 mg/dL in children <13 years of age or ≤7.5 mg/dL in those ≥13 years of age) achieved within 48 hours following initiation of rasburicase therapy.^{1 3}

Duration

Target plasma uric acid concentrations maintained for 24 hours after the last administered rasburicase dose.^{1 3}

Distribution

Extent

Not known whether rasburicase is distributed into milk.^a

Elimination

Half-life

18 hours.^a

Stability

Storage

Parenteral

Powder for Injection and Diluent

2–8°C.¹ Do not freeze; protect from light.^a

ActionsActions

• 
  

  Catalyzes oxidation of uric acid into an inactive and soluble metabolite (allantoin).¹

  
  


• 
  

  Active only at the end of the purine catabolic pathway that produces uric acid.¹

  
  

Advice to Patients

• 
  

  Risk of hypersensitivity reactions (e.g., anaphylaxis).¹ Importance of immediately seeking medical attention if symptoms of severe sensitivity (e.g., chest pain, dyspnea, hypotension, urticaria) occur.¹

  
  


• 
  

  Risk of adverse hematologic effects (e.g., hemolysis, methemoglobinemia).¹

  
  


• 
  

  Importance of women informing clinicians immediately if they are or plan to become pregnant or plan to breast-feed.¹

  
  


• 
  

  Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.^a

  
  


• 
  

  Importance of informing patients of other important precautionary information. (See Cautions.)

  
  

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Rasburicase

Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Parenteral	For IV infusion	1.5 mg	Elitek	Sanofi-Aventis

Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.

The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions March 2007. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

References

1. Sanofi-Aventis Inc. Elitek (rasburicase) injection for intravenous use prescribing information. New York, NY; 2002 Jul 22.

2. Goldman SC, Holcenberg JS, Finklestein JZ et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 2001; 97:2998-3003. [IDIS 463743] [PubMed 11342423]

3. Pui CH, Mahmoud HH, Wiley JM et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol. 2001; 19:697-704. [IDIS 460147] [PubMed 11157020]

4. Easton J, Noble S, Jarvis B. Rasburicase. Pediatr Drugs. 2001; 3:433-9

5. Anon. Rasburicase (Elitek) for hyperuricemia. Med Letter Drug Ther. 2002; 44:96-7.

6. Lohr LK. Rasburicase, a new, recombinate form of urate oxidase, treats hyperuricemia in tumor lysis syndrome. Hem/Onc Today. October 2002. From the Hem/Onc Today website. Accessed 2003 Jan 23.

7. Smalley RV, Guaspari A, Haase-Statz S et al. Allopurinol: intravenous use for prevention and treatment of hyperuricemia. J Clin Oncol. 2000; 18:1758-63. [IDIS 447152] [PubMed 10764437]

8. Nabi Biopharmaceuticals. Aloprim (allopurinol sodium) for injection, for intravenous infusion prescribing information (dated 1999 Jun). In: Physicians’ desk reference. From the PDR electronic library website. Accessed 2003 Jan 27.

9. Sanofi-Aventis Inc., New York, NY: Personal communication.

a. Sanofi-Aventis Inc. Elitek (rasburicase) injection for intravenous use prescribing information. New York, NY; 2005 Mar.

More Rasburicase resources

• Rasburicase Side Effects (in more detail)
• Rasburicase Use in Pregnancy & Breastfeeding
• Rasburicase Support Group
• 0 Reviews for Rasburicase - Add your own review/rating

• Rasburicase Professional Patient Advice (Wolters Kluwer)


• Rasburicase MedFacts Consumer Leaflet (Wolters Kluwer)


• rasburicase Concise Consumer Information (Cerner Multum)


• rasburicase Intravenous Advanced Consumer (Micromedex) - Includes Dosage Information


• Elitek Prescribing Information (FDA)

Compare Rasburicase with other medications

• Hyperuricemia Secondary to Chemotherapy

Morfinesulfaat Actavis

Morfinesulfaat Actavis may be available in the countries listed below.

Ingredient matches for Morfinesulfaat Actavis

Morphine

Morphine sulphate pentahydrate (a derivative of Morphine) is reported as an ingredient of Morfinesulfaat Actavis in the following countries:

• Netherlands

International Drug Name Search

Equetro

Equetro is a brand name of carbamazepine, approved by the FDA in the following formulation(s):

EQUETRO (carbamazepine - capsule, extended release; oral)

• 
  Manufacturer: VALIDUS PHARMS INC
  
  Approval date: December 10, 2004
  
  Strength(s): 100MG, 200MG, 300MG ^[RLD]

Has a generic version of Equetro been approved?

No. There is currently no therapeutically equivalent version of Equetro available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Equetro. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
  Patent 5,326,570
  Issued: July 5, 1994
  Inventor(s): Rudnic; Edward M. & Belendiuk; George W.
  Assignee(s): Pharmavene, Inc.
  The present invention relates to a composition and method of treating a patient by administering carbamazepine in a pharmaceutical dosage form capable of maintaining the patient's blood concentration at from about 4 .mu.g/ml to about 12 .mu.g/ml over at least a 12 hour period, where the blood concentration of carbamazepine does not vary by more than 60 percent.
  
  Patent expiration dates:
  
  
  • July 23, 2011
    
    ✓ 
    Patent use: TREATMENT OF PATIENTS USING EXTENDED-RELEASE CARBAMAZEPINE
    ✓ 
    Drug product
  
  



• 
  Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
  Patent 5,912,013
  Issued: June 15, 1999
  Inventor(s): Rudnic; Edward M. & Belendiuk; George W. & McCarty; John & Wassink; Sandra & Couch; Richard A.
  Assignee(s): Shire Laboratories, Inc.
  The present invention relates to a composition and method of treating a patient by administering carbamazepine in a pharmaceutical dosage form capable of maintaining the patient's blood concentration at from about 4 .mu.g/ml to about 12 .mu.g/ml over at least a 12 hour period, where the blood concentration of carbamazepine does not vary by more than 60 percent.
  
  Patent expiration dates:
  
  
  • June 15, 2016
    
    ✓ 
    Drug product
  
  



• 
  Methods for the treatment of bipolar disorder using carbamazepine
  Patent 6,977,253
  Issued: December 20, 2005
  Inventor(s): Kalali; Amir H. & Tulloch; Simon J.
  Assignee(s): Shire Pharmaceutical Development Inc.
  Carbamazepine, in extended release form, is useful in the treatment of patients suffering from bipolar disorder. In order to minimize the time it takes to reach efficacy, carbamazepine, in extended release form, can be administered to the patient at an initial daily dose which is then increased in daily increments until clinical efficacy is achieved.
  
  Patent expiration dates:
  
  
  • May 19, 2024
    
    ✓ 
    Patent use: THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.
  
  

See also...

• Equetro Consumer Information (Drugs.com)
• Equetro Sustained-Release Capsules Consumer Information (Wolters Kluwer)
• Equetro Consumer Information (Cerner Multum)
• Equetro Advanced Consumer Information (Micromedex)
• Carbamazepine Consumer Information (Drugs.com)
• Carbamazepine Consumer Information (Wolters Kluwer)
• Carbamazepine Chewable Tablets Consumer Information (Wolters Kluwer)
• Carbamazepine Suspension Consumer Information (Wolters Kluwer)
• Carbamazepine Sustained-Release Capsules Consumer Information (Wolters Kluwer)
• Carbamazepine Sustained-Release Tablets Consumer Information (Wolters Kluwer)
• Carbamazepine Consumer Information (Cerner Multum)
• Carbamazepine Advanced Consumer Information (Micromedex)
• Carbamazepine AHFS DI Monographs (ASHP)

Risperidon TAD

Risperidon TAD may be available in the countries listed below.

Ingredient matches for Risperidon TAD

Risperidone

Risperidone is reported as an ingredient of Risperidon TAD in the following countries:

• Germany


• Poland

International Drug Name Search

Doxydyn

Doxydyn may be available in the countries listed below.

Ingredient matches for Doxydyn

Doxycycline

Doxycycline hyclate (a derivative of Doxycycline) is reported as an ingredient of Doxydyn in the following countries:

• Austria

International Drug Name Search

Piridoksin

Piridoksin may be available in the countries listed below.

Ingredient matches for Piridoksin

Pyridoxine

Pyridoxine hydrochloride (a derivative of Pyridoxine) is reported as an ingredient of Piridoksin in the following countries:

• Serbia

International Drug Name Search

Aluminium Oxide

ATC (Anatomical Therapeutic Chemical Classification)

D10AX04

CAS registry number (Chemical Abstracts Service)

0001344-28-1

Chemical Formula

Al2-O3

Molecular Weight

101

Therapeutic Categories

Dermatological agent

Pharmaceutic aid

Antiacne agent for topical use

Chemical Name

Aluminium oxide

Foreign Names

• Aluminii oxidum (Latin)
• Aluminiumoxid (German)
• Aluminium, oxyde d' (French)
• αxido de aluminio (Spanish)

Generic Names

• Alumina (IS)
• Aluminium oxyde (IS: ATC)
• Alumina, activated (IS)
• Aluminii oxidum hydricum (PH: Ph. Eur. 6)
• Aluminium oxide, hydrated (PH: Ph. Eur. 6)
• Aluminiumoxid, wasserhaltiges (PH: Ph. Eur. 6)
• Dried Aluminium Hydroxide (PH: BP 2010)
• Oxyde d'aluminium, hydraté (PH: Ph. Eur. 6)

Brand Name

• Rocgel
  Dexo, France

International Drug Name Search

Glossary

IS	Inofficial Synonym
PH	Pharmacopoeia Name

Click for further information on drug naming conventions and International Nonproprietary Names.